trial

Study Evaluating The Safety and Tolerability of HTC-867 in Healthy Japanese Subjects

NCTId NCT01268124
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 56 (actual)
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer
Primary completion 2009-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
56 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2008-12
Primary completion
2009-04
Eligibility
MALE · 20 Years · 45 Years

Interventions & indications

Drugs
HTC-867

Sponsors

Wyeth is now a wholly owned subsidiary of PfizerLead Sponsor

Sites

0 total

Facts & assertions

4 sourced
Enrollment
56
Phase
PHASE1
Primary Completion Date
2009-04
Status
COMPLETED
relationships
The graph out of here
drug
HTC-867
drug
lead_sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
company
indication
Schizophrenia
indication
Schizophrenia
indication